Non-neurotoxic plasminogen activating factors for treating of stroke
AssigneePaion Company, Limited
InventorsMariola SOHNGEN, Wolfgang Sohngen, Wolf-Dieter Schleuning, Robert Medcalf
Life of this patent
Estimating the term…
Abstract
The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.
Claims11
1-43. (canceled)
A method for treating stroke comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition consisting essentially of a plasminogen activating factor,
- wherein the plasminogen activating factor is DSPAα1 or a microheterogeneous form thereof;
- and
- wherein the plasminogen activating factor is administered more than 3 hours after onset of a stroke.
A method for treating stroke comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition consisting essentially of a plasminogen activating factor,
- wherein the plasminogen activating factor is recombinantly produced;
- wherein the plasminogen activating factor is an allelic variant of DSPAα1;
- and
- wherein the plasminogen activating factor is administered more than 3 hours after onset of a stroke.
Dependencies are inferred from the claim text.